Sten Myrehaug

Sten Myrehaug

Auto-generated profile, based on publicly available information

Sten Myrehaug

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of Neurosurgery: Spine
Verified
Journal Article
Closed access
SMSten Myrehaug
Sten Myrehaug
ASArjun Sahgal
Arjun Sahgal
MHMotohiro Hayashi
Motohiro Hayashi
MLMarc Levivier
Marc Levivier
LMLijun Ma
Lijun Ma
ASAntonio De Salles
Antonio De Salles
OBJECTIVE: Spinal metastases that recur after conventional palliative radiotherapy have historically been difficult to manage due to concerns of spinal cord toxicity in the retreatment setting. Spine stereotactic body radiation therapy (SBRT), also known as stereotactic radiosurgery, is emerging as an effective and safe means of delivering ablative doses to these recurrent tumors. The authors performed a systematic review of the literature to determine the clinical efficacy and safety of spine SBRT specific to previously irradiated spinal metastases.METHODS: A systematic literature review was conducted, which was specific to SBRT to the spine, using MEDLINE, Embase, Cochrane Evidence-Based Medicine Database, National Guideline Clearinghouse, and CMA Infobase, with further bibliographic review of appropriate articles. Research questions included: 1) Is retreatment spine SBRT efficacious with respect to local control and symptom control? 2) Is retreatment spine SBRT safe?RESULTS: The initial literature search retrieved 2263 articles. Of these articles, 160 were potentially relevant, 105 were selected for in-depth review, and 9 studies met all inclusion criteria for analysis. All studies were single-institution series, including 4 retrospective, 3 retrospective series of prospective databases, 1 prospective, and 1 Phase I/II prospective study (low- or very low–quality data). The results indicated that spine SBRT is effective, with a median 1-year local control rate of 76% (range 66%–90%). Improvement in patients’ pain scores post-SBRT ranged from 65% to 81%. Treatment delivery was safe, with crude rates of vertebral body fracture of 12% (range 0%–22%) and radiation-induced myelopathy of 1.2%.CONCLUSIONS: This systematic literature review suggests that SBRT to previously irradiated spinal metastases is safe and effective with respect to both local control and pain relief. Although the evidence is limited to low-quality data, SBRT can be a recommended treatment option for reirradiation.

1 May 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KZKang Liang Zeng
Kang Liang Zeng
CTChia-Lin (Eric) Tseng
Chia-Lin (Eric) Tseng
HSHany Soliman
Hany Soliman
YWYonatan Weiss
Yonatan Weiss
ASArjun Sahgal
Arjun Sahgal
SMSten Myrehaug
Sten Myrehaug
The oligometastatic state is hypothesized to represent an intermediary state of cancer between widely metastatic disease and curable, localized disease. Advancements in radiotherapy have allowed for delivery of high precision, dose escalated treatment known as stereotactic body radiotherapy (SBRT) to targets throughout the body with excellent rates of local control. Recently, the first phase II randomized trial comparing conventional radiotherapy to comprehensive SBRT of oligometastatic disease demonstrated an overall survival and progression free survival advantage. The spine is a common site of metastasis, and a complex site for SBRT given the adjacent spinal cord and the tumor embedded within the bone tissue putting the patient at risk of fracture. Although there are expert spine SBRT guidelines for practice, there are as yet no reported randomized trials that proves superiority as compared to conventional radiation. The use of SBRT in patients with oligometastatic disease and spinal metastases is the focus of this review.

13 February 2020 in Practical Radiation Oncology
Verified
Journal Article
Closed access
EKEugene J. Koay
Eugene J. Koay
AHAlexander N. Hanania
Alexander N. Hanania
WHWilliam A. Hall
William A. Hall
Cullen M. TaniguchiCullen M. Taniguchi
Cullen M. Taniguchi
NRNeal Rebueno
Neal Rebueno
BEBeth Erickson
Beth Erickson

15 May 2023 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
JEJennifer R Eads
Jennifer R Eads
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
TATim Asmis
Tim Asmis
ABAndrew M. Bellizzi
Andrew M. Bellizzi
EBEmily Bergsland
Emily Bergsland
JCJennifer A Chan
Jennifer A Chan
High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.

1 March 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JSJames Stewart
James Stewart
ASArjun Sahgal
Arjun Sahgal
YLYoung Lee
Young Lee
HSHany Soliman
Hany Soliman
CTChia-Lin Tseng
Chia-Lin Tseng
SMSten Myrehaug
Sten Myrehaug

1 November 2019 in British Journal of Radiology
Verified
Journal Article
Closed access
MMMahmud Mossa-Basha
Mahmud Mossa-Basha
PGPeter C. Gerszten
Peter C. Gerszten
SMSten Myrehaug
Sten Myrehaug
NMNina A. Mayr
Nina A. Mayr
WYWilliam Tc Yuh
William Tc Yuh
SLSimon Lo
Simon Lo
Spine metastatic disease is an increasingly common occurrence in cancer patients due to improved patient survival. Close proximity of the bony spinal column to the spinal cord limits many conventional treatments for metastatic disease. In the past decade, we have witnessed dramatic advancements in therapies, with improvements in surgical techniques and recent adoption of spine stereotactic radiotherapy techniques leading to improved patient outcomes. Multidisciplinary approaches to patient evaluation, treatment and follow-up are essential. Imaging plays an ever increasing role in disease detection, pre-treatment planning and assessment of patient outcomes. It is important for the radiologist to be familiar with imaging algorithms, best practices for surgery and/or radiotherapy and imaging findings in the post-treatment period that may indicate disease recurrence. In this review, we present a multidisciplinary discussion of spine metastases, with specific focus on pre-treatment imaging, planning, current treatment approaches, and post-treatment assessment.